Quanterix CORP Schedule 13D activist filings

Activist investor Kent Lake Partners LP has reduced its beneficial ownership in Quanterix Corp to 4.5% through recent share sales, while simultaneously re-nominating three individuals for election to the Board of Directors at the rescheduled 2025 annual meeting.

Akoya Biosciences, Inc. has terminated its Voting and Support Agreement with certain Quanterix Corp. stockholders, a procedural step following the execution of an Amended and Restated Agreement and Plan of Merger.

Quanterix Corporation has amended its merger agreement with Akoya Biosciences, Inc., outlining revised acquisition terms and securing voting support from key Akoya shareholders representing 55.6% of outstanding common stock.

Activist investor Kent Lake Partners LP, along with its affiliates and Benjamin Natter, has formally nominated three director candidates for election to Quanterix Corporation's Board of Directors at the 2025 annual meeting, holding a 6.9% beneficial ownership stake.

Activist investor Kent Lake Partners, holding a 5.91% stake in Quanterix Corp, has publicly opposed the company's proposed stock merger with Akoya Biosciences, calling it a 'bailout' that significantly undervalues Quanterix and risks its financial stability.

Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. through a merger, with Akoya becoming a wholly-owned subsidiary of Quanterix, significantly altering the combined entity's ownership structure and board composition.

Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. in an all-stock transaction, with Akoya becoming a wholly-owned subsidiary of Quanterix.